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Optimisation of a potent series of HCV helicase drug candidates 
Introduction 
 
Infection with the Hepatitis C virus (HCV) has recent-
ly become the second commonest chronic viral disease 
in the world. It is believed that its global prevalence 
exceeds 180 million people worldwide. That is over 
3% of the world population, who are chronically in-
fected with the virus (Brass et al. 2006). Progression of 
HCV infection usually results in liver cirrhosis and/or 
hepatocellular carcinoma (Craxì et al. 2008). To date, 
there is neither vaccination available nor any prophy-
lactic approach against HCV infection and such vac-
cine is not expected anytime soon (Hayashi & Takeha-
ra 2006). Current treatment of HCV infected patients 
involves the co-administration of pegylated interferon 
with ribavirin, which is associated with serious clinical 
adverse effects. There is a range of recent drug candi-
dates that are currently in preclinical or clinical devel-
opment stages. However, most of those drugs aim ei-
ther the protease or the polymerase enzymes of the 
Hepatitis C virus (Lam & Frick 2006). Provided that 
years of extensive research concerning the latter en-
zymes have failed to come up with an answer to the 
HCV infection, new targets must be identified. One of 
the most important novel targets today is the HCV hel-
icase enzyme. There has been no extensive research on 
the HCV helicase, even though it is one of the most 
important enzymes for the survival and proliferation of 
the virus (Bailey et al. 1997, Janetka et al. 2000, Maga 
et al. 2005, Soriano et al. 2009, Zhang et al. 2003). 
The role of the HCV helicase is to unwind double 
stranded RNA (dsRNA) into single stranded RNA 
(ssRNA) during the viral replication cycle. Conse-
quently, inhibition of the HCV helicase would inter-
rupt the viral replication life cycle.  
 
Current Research 
 
Only recently we introduced and published a novel and 
successful de novo structure-based drug design ap-
proach on the HCV helicase (Kandil et al. 2009). 
Computer-aided drug design followed by extensive 
molecular dynamics simulations, helped establish a 
series of novel compounds, capable of interacting with 
the putative binding site on the HCV helicase ssRNA 
channel. Our best-ranking compounds were chemically 
synthesised and biologically evaluated against the pu-
rified enzyme. They exhibited inhibition of the HCV 
helicase enzyme in submicromolar concentrations. Our 
rational drug design approach was based on the struc-
ture of the HCV helicase, obtained by X-ray crystal-
lography (Kim et al. 1998). In one of these crystals, 
the HCV helicase was co-crystallised with a single 
strand of a DNA fragment, providing invaluable infor-
mation about the interaction pattern of the oligonucleo-
tide with the enzyme. Conserved “key” residues were 
soon isolated and selected as suitable amino acid tar-
gets for the structure-based drug design approach. No-
tably the most important one was an Arginine amino 
acid (Arg393), which was clearly involved in interac-
tions with the DNA fragment. Molecular biology stud-
ies on the HCV helicase confirmed that upon mutation 
of the Arg393 to an Ala amino acid (R393A) the en-
zyme loses its unwinding properties (Lam et al. 2003). 
It was evident that the Arg393 amino acid was respon-
sible for the processing of the viral genetic material. 
By further observing the HCV helicase crystal struc-
ture we noticed that a Cysteine amino acid (Cys431) 
managed to establish a disulphide bond with a mercap-
toethanol molecule that was present in the crystallisa-
tion solution. Cys431 was located around ~10Å away 
from Arg393 and constituted an ideal target for drug 
design. Since it was able to interact with the mercap-
toethanol molecule, it was definitely exposed and reac-
tive enough to form a disulphide bond. A compound 
capable of covalently bonding with Cys431 would be 
impossible to be displaced by the incoming oligonucle-
otide, water or any other solvent ions, in contrast to 
competitive drugs that establish bonds of electrostatic 
or hydrophobic nature. 
 Eventually, the in silico drug design part was 
finished and our most promising compounds were 
chemically synthesised and biologically evaluated by a 
strand-displacement enzymatic assay against the HCV 
helicase enzyme. Compound no. 4 produced an IC50  of 
0.26µM, while at the same time its regioisomer Com-
Journal of Molecular Biochemistry (2015) 4, 1-4 © The Author(s) 2015. Published by Lorem Ipsum Press. 
pound no. 12 did not show any activity at all (Figure 
1). That can be explained by our molecular modelling 
analysis, where the 2-4 substituted pyrrole did not in-
teract with the Michael acceptor moiety positioned in 
proximity to the Cys431 amino acid. The potency and 
inhibitory properties of Compound no. 4 were then 
confirmed by biological evaluation on HCV subge-
nomic replicon replication assay. Compound no. 4 
turned out to be quite cytostatic to the hepatoma cells 
with an EC50 value of 3µg/ml and a IC50 value of 
10µg/ml. (Kandil et al. 2009). That could possibly be 
explained by the fact that the vinyl ketone moiety is a 
known potent toxicophore. The ester analogues were 
also synthesized and tested, although our in silico 
model suggests that the free acid version of that com-
pound should be capable of improved interaction with 
Arg393 and Cys431 amino acids. However it must be 
noted that the increased polarity and charges of the 
above compounds could affect the cellular permeabil-
ity of the drugs. 
 
What the future holds 
 
We have reached a critical point in our research where, 
we need to further exploit our existing work on the 
helicase inhibitors in order to achieve a better under-
standing of the mechanism of action of those mole-
cules and proceed with the design and development of 
an improved series of compounds as drug candidates 
against the Hepatitis C Virus (Figure 2). The first step 
will be the lead optimization process of our most po-
tent compounds using computer-aided in silico tech-
niques, starting from Compound no. 4. The drug de-
sign process based on our previous compounds is very 
promising, since the sample that will be used here is 
from a pool of highly active compounds (Balatsos et 
al. 2012, Dalkas et al. 2012, Loukatou et al. 2014, Pa-
pangelopoulos et al. 2013). Further in silico studies 
must be incorporated in an attempt to minimize the 
potential adverse effects of our drug candidates. Using 
large databases and bioinformatics tools we aim to 
generate an improved series of drug candidates against 
the HCV helicase that will still have the same inhibito-
ry potency, but far less toxicity and improved bioavail-
ability (Papageorgiou et al. 2013, Sellis et al. 2009, 
Vlachakis et al. 2013a).  
 The new line of improved drug candidates will 
be initially evaluated in silico for their predicted effica-
cy against the HCV enzymes. That involves molecular 
docking, energy minimizations, molecular dynamics 
and Monte Carlo simulations (Vlachakis et al. 2013c). 
As soon as the computer-aided simulations are over 
the best ranking compounds will be chemically synthe-
sized. Since all drug candidates descent from our cur-
rent lead compounds, the major part of the synthetic 
pathway is known to us and already improved in such 
a way that we may obtain large quantities of highly 
pure product within a very limited time-course 
(Vlachakis et al. 2013d, Vlachakis & Kossida 2013). 
Finally, an enzymatic assay will help determine the in 
vitro activity of the newly synthesized drug candidates. 
The enzymatic assay has been customly developed for 
rapid testing of small molecule drugs against the hel-
icase protein of HCV (unpublished data). Our assay 
can determine the potency of a certain compound with-
in a few hours and speed up the screening process that 
is usually the bottleneck of biological evaluations 
(Vlachakis et al. 2013e). All compounds that exhibit at 
least some activity in our enzymatic assay will be fur-
ther tested in a replicon cellular assay that will provide 
us with invaluable information about the bioavailabil-
ity and toxicity levels of each drug candidate. Eventu-
ally it is our aim to obtain a crystal structure of the 
complex to validate our approach. This in turn may 
allow to further rationally optimize these compounds 
and to obtain a more specific and mechanism driven 
class of potent anti-HCV inhibitors (Vlachakis et al. 
2012, 2013b,f, 2014).  
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Figure 1. Left: The docked complex of the HCV helicase. The inhibitor covalently bonds with Cys431, while bridging the 
ssRNA channel via interactions with Arg393. Right: The chemical structures of Compounds 4 and 12. 
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Conclusion 
 
In conclusion, we have used a de novo approach to 
design a novel HCV helicase inhibitor that could target 
a newly identified pocket on the enzyme. Our com-
pounds propose a novel and unique approach to the 
battle against HCV. They are the only compounds 
known to literature capable of covalently interacting 
with the ssRNA channel of the helicase enzyme of 
HCV, while at the same time being very easy and 
cheap to synthesize, in compliance with the huge phar-
macoeconomic issues that run though most of the 
countries that suffer from HCV epidemics. Further-
more, they have demonstrated activity within submi-
cromolar concentrations, when evaluated in biological 
in vitro and replicon cellular assays. Funding and con-
tinuation of our work would enable the exploitation of 
our drug candidates in order to further improve them 
and subject them in clinical trials, aiming for a signifi-
cant contribution to the fight against the lethal HCV 
epidemic. 
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